NC
SMMT icon

nVerses Capital’s Summit Therapeutics SMMT Stock Holding History

nVerses Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Buy
+17,749
New +$315K 0.4% 95

Other funds holding SMMT

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

nVerses Capital's SMMT Position: Q2 2026 in Review

nVerses Capital opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 17,749 shares worth $259K. The stake represents 0.4% of the portfolio and ranks #95 among its holdings.

155 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • nVerses Capital held 17,749 shares of Summit Therapeutics worth $259K as of Q2 2026.
  • Summit Therapeutics was a new nVerses Capital position in Q2 2026.
  • Summit Therapeutics made up 0.4% of nVerses Capital's portfolio in Q2 2026, its #95 holding.
  • 155 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.